Born 1953. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. He was previously Adjunct Professor at the Karolinska Institute and has extensive experience from leading R&D positions in the pharmaceutical industry. He has over 20 years of experience in different Global R&D management positions at AstraZeneca and contributed to more than a dozen successful global product registrations for medicines in cardiovascular, vascular and gastrointestinal indications. Dr. Gunnar Olsson has been on the board of ESC, that awarded him the ESC President Award in recognition of his outstanding lifetime achievements, in 2023.
Dr. Gunnar Olsson is the CEO and Board Member of IRLAB Therapeutics AB. He is also a Board Member in, among others, Amplifier Tx AB, and Gesynta Pharma AB as well as being Vice Chair for the Swedish Heart Lung Foundation and Bundy Academy, Lund University. He was a Board Member in Cereno Scientific between 2016-2018 and has been a Member of the Scientific Advisory Board since this was established in 2019. Dr. Gunnar Olsson has been a Senior Advisor to the Executive Management Team since 2018 and is a Member of the Clinical Steering Committee of the ongoing clinical Phase II study with CS1 in PAH.